Since the 1990s, elevated serum levels of IL-6 have been associated with worse survival in breast cancer patients (Zhang and Adachi, 1999; Salgado et al., 2003; Knüpfer and Preiss, 2007). Here, IL6 is linked to breast carcinoma.